NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER
First Prospective Study of Treatment in Patients with Wild-Type RAS Colorectal Cancer and Left-Sided Primary Tumor Results From the Phase 3 PARADIGM Trial Being Featured During ASCO 2022 Plenary Session THOUSAND OAKS, Calif. and OSAKA, Japan, June 5, 2022 /PRNewswire/ — Amgen…
Comments Off on NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER